Please find enclosed herewith Outcome of Board Meeting Pursuant to regulation 30 of Sebi (LODR)Regulation ,2015 held on today i.e. 15th October 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved the standalone unaudited financial results for the quarter and half-year ended 30 September 2025, accompanied by an unqualified limited review report from Andros & Co. Revenue from operations fell sharply to ₹9 lakh in Q2 FY26 from ₹20.5 lakh in Q2 FY25, a drop of roughly 56% year-on-year, while H1 FY26 revenue halved to ₹18 lakh from ₹36 lakh a year earlier. Profit after tax collapsed to about ₹33,049 in Q2 FY26 (vs ₹14.76 lakh in Q2 FY25) and ₹2.80 lakh for H1 FY26 (vs ₹27.52 lakh), with EPS slipping to ₹0.09 from ₹0.90. The cash flow statement shows the company burnt ₹3.82 lakh in operating activities during H1 FY26 (vs ₹41.21 lakh generated last year), and closing cash has dwindled to just ₹70,690 against ₹4.52 lakh at the start of the year.
The steep top-line and bottom-line contraction, combined with negative operating cash flow and an extremely thin cash cushion, points to significant operational stress for shareholders. The stock is small-cap and illiquid; investors should expect heightened earnings volatility and reassess risk given the sharp fall in profitability and weakening cash position.